ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025
Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe oral formulation of the glucagon-like peptide-1 receptor agonist semaglutide has dosing requirements that could impact adherence. We compared perceptions of physicians and individuals with type 2 diabetes (T2D) in Japan, before and after initiating oral semaglutide, with respect to adherence to dosing requirements.
methodsIn this observational study, online questionnaires were completed by treating physicians and adults with T2D who had received either oral semaglutide or other oral antidiabetic medications for ≥ 6 months. Physicians reported the expected adherence of their patients to oral semaglutide and expected patient difficulties around the dosing requirements prior to (baseline) and after (time of survey) initiating oral semaglutide. Patient-reported adherence and difficulties experienced with the dosing requirements were assessed after oral semaglutide was initiated.
resultsOverall, 330 physicians and 412 individuals with T2D responded. There was a statistically significant difference (P < 0.001) between baseline and time of survey in the distribution of physicians who expected that ≥ 80% or < 80% of their patients would adhere to oral semaglutide, with 17.2% of physicians expecting ≥ 80% of their patients to be adherent before treatment initiation versus 44.6% reporting ≥ 80% of their patients to be adherent after treatment initiation. There was also a statistically significant difference (P < 0.001) in the distribution of expected versus reported adherence among individuals who received oral semaglutide. After semaglutide initiation, 95.2% of patients reported missing ≤ 1 dose/week. Before prescribing oral semaglutide, 186 (56.4%) physicians were resistant to it, due to the dosing requirements. After prescribing oral semaglutide, 146 (44.2%) reported their resistance had decreased, whereas only 28 (8.5%) reported increased resistance.
conclusionsWe identified an improvement in physician perceptions of oral semaglutide adherence due to dosing requirements following semaglutide initiation. Our findings suggest that individuals with T2D in Japan are capable of adhering to the dosing requirements of oral semaglutide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.